REGENXBIO INC (RGNX)
Health Care · Biotechnology - Gene Therapy · NASDAQ
A clinical-stage gene therapy developer leveraging its proprietary AAV platform to create potentially curative, one-time treatments for serious genetic diseases.
What REGENXBIO INC does
REGENXBIO is a clinical-stage biotechnology company developing one-time gene therapies for retinal, neuromuscular, and neurodegenerative diseases. Its proprietary NAV Technology Platform uses adeno-associated virus (AAV) vectors to deliver functional genes. The company collaborates with AbbVie for its lead retinal program and with Nippon Shinyaku for its neurodegenerative program.
Recent developments
In July 2026, the company raised over $200 million via a $100 million milestone payment from AbbVie and an underwritten public offering to extend its cash runway into Q4 2027. The company's Phase III trial for RGX-202 met its primary endpoint, and it remains on track for a BLA submission in Q3 2026. Topline data for the pivotal wet AMD subretinal trials are expected in Q4 2026.
From REGENXBIO INC's filing of 2026-08-06.
Themes: gene therapy, AAV delivery platform, retinal disease, Duchenne muscular dystrophy, rare genetic diseases
Fundamentals
- Price$8.09 as of 2026-10-08 close
- Market cap$534M as of 2026-07-31 (share count; price 2026-10-08)
- 1-year return-33.8% 2025-10-08 close $12.22 → 2026-10-08 close $8.09
- P/En/a negative earnings
- Net margin-113.8% FY2025, SEC XBRL
- ROE-188.7% FY2025, SEC XBRL
- Debt / equity2.53 as of 2026-09-02
- Revenue growth (YoY)+12.0% as of 2026-09-02
- Revenue CAGR (3y)+14.8% SEC XBRL
- Beta1.88 as of 2026-09-02
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How RGNX compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-02
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-02
- return on equitybottom 10% 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How REGENXBIO INC looks technically
REGENXBIO INC (RGNX) is trading 17.7% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 16 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 49, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 6 trading days ago (its momentum flipped positive). It made a new 20-day low about 11 trading days ago. It is 50.0% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 17.7% below its 200-day average, the long-term trend line — a long-term downtrend | -17.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $9.12 | $9.12 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $9.83 | $9.83 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 7.12. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a five-part sequence in leg 4. | possible three-wave downward correction, complete (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 16 trading days ago — a "death cross", a bearish long-term signal | 16 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend) | 17.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 49, neither overbought (above 70) nor oversold (below 30) | 49.0 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($7.12 to $8.31) — its "stochastic" reading is 81 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 81.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 6 trading days ago (its momentum flipped positive) | 6 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $16.19 | $16.19 |
|---|---|---|
| From the 52-week high | it is 50.0% below its 52-week high (its highest price of the past year) | -50.0% |
| Above the 52-week low | it is 48.2% above its 52-week low (its lowest price of the past year) | +48.2% |
| Below the 52-week high | it is 50.0% below its highest point of the past year | 50.0% |
| Since a 20-day breakout | it made a new 20-day low about 11 trading days ago | 11 sessions |
| Since a 55-day breakout | it made a new 55-day low about 11 trading days ago | 11 sessions |
| All-time high | its highest closing price on record is $85.10 (set on 2018-07-10) | $85.10 |
| Given back of the 52-week move | over the past year its closes ranged ($5.65 to $15.98), and it has recovered roughly a quarter of its fall from last year’s high — 24% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $12.03 to $12.36. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 23.6% |
| From the all-time high | it is 90.5% below its all-time high | -90.5% |
| Nearest price level | it is trading 0.7% below a resistance level at $8.14 — a price it turned at twice since 2025-07-21, most recently on 2026-04-29. Since 2024-10-08 it has 6 such levels below the current price and 11 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.7% |
| All-time low | its lowest closing price on record is $5.04 (set on 2025-04-09) | $5.04 |
| Above the all-time low | it is 60.7% above its all-time low | +60.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 86% of it) | 14th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.5545 between its high and its low — about 6.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.5545 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $7.00 and $8.58 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $7.00 – $7.79 – $8.58 |
| Typical daily range (% of price) | its price moves about 6.9% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.8% |
| Stretch from the 200-day average | it is trading 3.2 daily ranges below its 200-day average price (17.7% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.2 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.65× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 3 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 3 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-08 1.3% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -1.3% |
|---|---|---|
| Open gap | it gapped 22.7% below the previous close 32 sessions ago and has not traded back through the level it left behind at 10.72 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -22.7% |
| Gap filled | a 5.0% gap up opened on 2026-10-05 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 2 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +8.59% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 8.7 percentage points (the stock lost 7.6% while the market gained 1.0%) | -8.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 50.7 percentage points (the stock lost 46.9% while the market gained 3.8%) | -50.7% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 25.5 percentage points (the stock lost 8.1% while the market gained 17.5%) | -25.5% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 48.8 percentage points (the stock lost 33.8% while the market gained 15.0%) | -48.8% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, near the top of its 14-day range (overbought), trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 19% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 23.5% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -18.5% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 15% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $9.50 — a volume-weighted average of daily closes over 191 sessions, not a true tick-by-tick VWAP. | -14.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is 8% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $8.75 — a volume-weighted average of daily closes over 45 sessions, not a true tick-by-tick VWAP. | -7.6% |
Price levels it has turned at before
RGNX last closed at $8.09 on 2026-10-08. Since 2024-10-08 it has turned at 6 prices below its last close and 11 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $8.14 | Resistance | 0.7% above the last close | turned there twice · 2025-07-21 to 2026-04-29 |
| $7.98 | Support | 1.4% below the last close | turned there twice · 2025-06-05 to 2026-03-05 |
| $7.81 | Support | 3.5% below the last close | turned there three times · 2025-06-23 to 2026-08-24 |
| $8.46 | Resistance | 4.6% above the last close | turned there three times · 2024-11-01 to 2026-07-17 |
| $7.59 | Support | 6.1% below the last close | turned there twice · 2026-02-19 to 2026-03-30 |
| $8.78 | Resistance | 8.6% above the last close | turned there four times · 2024-11-19 to 2025-09-22 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $7.12.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
Alternate reading: The same swings also read as a five-part sequence in leg 4, which fails on a close above $8.42.
This reading has stood for 6 trading days, since 2026-10-01.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Recent death cross (50-day crossed below 200-day) · Pulled back from the 12-month high · trendless / choppy (low ADX) · lagging the market · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.64 mean, 1=Strong Buy…5=Strong Sell) — 11 analysts
- Mean price target$23.73 range $10.00 – $50.00; median $19.00
Analyst estimates, as of 2026-10-05. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for RGNX
- Consensus EPS estimate-$1.27 next reporting period, as of 2026-10-05
- Estimate change, 30 days$0.00 from -$1.27, on 2026-08-31, 35-day window
- Readings revised upward0% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Heavy reliance on successful clinical trial results for regulatory approval.","Significant ongoing operating losses and potential need for additional capital.","Risks associated with developing and manufacturing complex biological therapies."]
What changed in the latest 10-Q
AI-assisted comparison of RGNX's 10-Q filed 2026-05-14 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references Annual Report on Form 10-K for year ended December 31, 2025, filed March 5, 2026 (vs. older filing references year ended December 31, 2024, filed March 13, 2025)
- Newer filing states sura-vec enrollment has been completed in AAVIATE trial
- Newer filing specifies NAAVIGATE is a two-part study with Phase IIb portion and Phase III expansion including part two of U.S. trial and parallel global trial led by AbbVie
- Newer filing states first patient dosing in NAAVIGATE expected in second quarter of 2026 with entitlement to $100.0 million milestone payment from AbbVie
- Newer filing reports Phase I/II results for RGX-202 reported between November 2024 and March 2026
- Newer filing reports RGX-202 Phase I/II had no serious adverse events or adverse events of special interest among all patients (n=13)
- Newer filing reports all pivotal dose RGX-202 patients exceeded 10% microdystrophin expression
- Newer filing reports five participants in RGX-202 Phase I/II exceeded expected disease trajectory on NSAA at one year (text truncated)
- Newer filing specifies AFFINITY DUCHENNE is for ambulatory patients aged 1 to 11 years old
- Removed:
- Older filing described sura-vec development with bullet point format listing multiple trial details
- Older filing stated AAVIATE 'continues to enroll a new cohort' at dose level 4 (indicating ongoing enrollment vs. completed)
- Older filing included historical January 2024 AAVIATE data regarding 106 patients, 80% reduction in annualized injection rate, and 50% injection-free outcomes
- Older filing included detailed safety specifics from July 29, 2024 such as episcleritis in three patients and absence of specific complications (endophthalmitis, vasculitis, etc.)
- Older filing stated 'Site selection for the Phase IIb/III trial is in progress' (vs. newer states enrollment initiated)
- Older filing included information about DME cohort in ALTITUDE with enrollment completed in June 2025
- Older filing stated RGX-202 trial designed to enroll approximately 30 patients in U.S. and Canada
- Older filing described AFFINITY DUCHENNE as evaluating patients aged 'one and older' (vs. newer specifies '1 to 11 years old')
- Reworded:
- Newer filing uses subsection heading 'Sura-vec for Treatment of Wet AMD' vs. older uses 'Wet AMD'
- Newer filing uses subsection heading 'Sura-vec for Treatment of DR and DME' vs. older uses 'DR and DME'
- Newer filing states sura-vec 'currently being evaluated' vs. older states ABBV-RGX-314 'is currently being evaluated'
- Newer filing states enrollment completed in ATMOSPHERE and ASCENT in October 2025 with topline data expected Q4 2026 'in partnership with AbbVie' (added phrase)
- Newer filing refers to 'sura-vec' consistently vs. older filing used both 'ABBV-RGX-314' and 'sura-vec'
- Newer filing describes ALTITUDE data as from August 2025 showing positive 2-year data vs. older describes August 2025 announcement of new data and planned pivotal program
- Newer filing states 'we and AbbVie announced an amendment to our collaboration agreement and plans to initiate' vs. older states 'we and AbbVie executed an amendment to our collaboration agreement and announced plans'
- Newer filing characterizes NAAVIGATE as 'two-part, multicenter, randomized, masked, sham-controlled Phase IIb/III study' vs. older states 'two-part sham injection-controlled Phase IIb/III trial'
- Newer filing specifies primary endpoint as '> 2-step improvement on the DRSS' vs. older uses '≥2-step DRSS improvement'
- Notes:
- Older filing text appears truncated at end of RGX-202 section; newer filing text also truncated at RGX-202 section end, limiting full comparison of that program's changes
- Comparison is between Q1 2026 filing (newer) and Q3 2025 filing (older), spanning approximately 6 months of clinical development
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
2 open-market purchases and 0 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-042 buys ($949381) · 0 sells — 1 buying insider
- Last 180 days · read to 2026-10-042 buys ($949381) · 4 sells ($886937) — 1 buying, 1 selling insiders
Activity heuristic: net buying (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-27. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about RGNX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding RGNX as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 11,478,003
- Reported value $137,506,484
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about RGNX's institutional holders → See what each manager we track holds →
Short interest (FINRA)
RGNX had 7,927,603 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
RGNX had 12.0% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.66 days to cover at the same settlement.
- Reported short interest (shares) 7,927,603
- Short interest (% of shares outstanding) 12.0%
- Prior settlement (shares) 7,497,221
- Reported change 5.74%
- Days to cover (reported) 7.66
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Sarepta Therapeutics (SRPT)
- Voyager Therapeutics (VYGR)
- Bluebird Bio (BLUE)
- Roche (RHHBY)
- Regeneron Pharmaceuticals (REGN)
- Bayer (BAYRY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare RGNX vs…
REGENXBIO INC is found in…
Frequently asked questions
What does REGENXBIO INC (RGNX) do?
REGENXBIO is a clinical-stage biotechnology company developing one-time gene therapies for retinal, neuromuscular, and neurodegenerative diseases. Its proprietary NAV Technology Platform uses adeno-associated virus (AAV) vectors to deliver functional genes. The company collaborates with AbbVie for its lead retinal program and with Nippon Shinyaku for its neurodegenerative program.
What sector is REGENXBIO INC (RGNX) in?
REGENXBIO INC (RGNX) is classified in the Health Care sector. Its industry is Biotechnology - Gene Therapy. It trades on NASDAQ.
Who are REGENXBIO INC's (RGNX) competitors?
Notable peers of REGENXBIO INC (RGNX) include Sarepta Therapeutics, Voyager Therapeutics, Bluebird Bio, Roche and Regeneron Pharmaceuticals. This peer set is informational only — not financial advice.
Is REGENXBIO INC (RGNX) overbought or oversold right now?
REGENXBIO INC (RGNX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 49, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on RGNX come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.